吉非替尼联合培美曲塞+顺铂治疗晚期肺腺癌的疗效评价

Efficacy of Gefitinib Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma

目的分析晚期肺腺癌行分子靶向药物吉非替尼联合培美曲塞+顺铂治疗的效果。方法选取2018年5月—2023年5月无锡市第二人民医院收治的62例晚期肺腺癌患者为研究对象,根据掷骰子分组,即化疗组、靶向组,各31例,化疗组行培美曲塞加顺铂治疗,靶向在化疗组基础上增加吉非替尼治疗,比较两组临床缓解率及不良反应总发生率。结果靶向组缓解率为64.52%,高于化疗组的35.48%,差异有统计学意义(χ^(2)=5.226,P<0.05)。靶向组不良反应总发生率为19.35%,化疗组为9.68%,两组比较,差异无统计学意义(χ^(2)=1.169,P>0.05)。结论吉非替尼联合培美曲塞+顺铂的效果好,能提升缓解率,不增加就诊期间的不良反应,对晚期肺腺癌患者较适用。

Objective To analyze the efficacy of gefitinib combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma.Methods 62 patients with advanced lung adenocarcinoma admitted to Wuxi Second People's Hospital from May 2018 to May 2023 were selected as the research objects,and they were divided into che⁃motherapy group and targeted group by dice,31 cases in each group.The chemotherapy group was treated with peme⁃trexed plus cisplatin,and the targeted group added with gefitinib therapy based on the chemotherapy group.Clinical remission rate and total incidence of adverse reactions were compared.Results The remission rate reached 64.52%in the targeted group,higher than 35.48%in the chemotherapy group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in total incidence of adverse reactions between 19.35%in the targeted group and 9.68%in the chemotherapy group(χ^(2)=1.169,P>0.05).Conclusion Gefitinib combined with peme⁃trexed plus cisplatin has a good effect,can improve the remission rate,and does not increase the adverse reactions dur⁃ing the visit,and is more suitable for patients with advanced lung adenocarcinoma.